Evidence-Based Heart Failure Medications and Cognition

Area of Science:

• Cardiology
• Neurology
• Gerontology

Background:

• Cognitive impairment is common in heart failure (HF) patients, with its causes debated.
• Physicians' reluctance to prescribe evidence-based HF medications stems from concerns about worsening cognition.
• This study investigated the association between HF medications and cognitive function in a large HF cohort.

Purpose of the Study:

• To determine if prescribing evidence-based heart failure medications is associated with cognitive function in patients with HF.
• To address physician concerns regarding the impact of HF treatments on cognitive health.
• To provide data supporting the use of guideline-directed medical therapy in HF patients with cognitive impairment.

Main Methods:

• Utilized data from 612 patients in the Rural Education to Improve Outcomes in Heart Failure clinical trial.
• Collected baseline information on medication prescriptions, including beta-blockers, ACE inhibitors, ARBs, diuretics, and aldosterone inhibitors.
• Assessed global cognitive function using the Mini-Cog screening tool.

Main Results:

• Global cognitive impairment was present in 34% (206 out of 612) of the study participants.
• No significant relationship was found between the prescription of evidence-based HF medications and global cognitive impairment.
• This lack of association persisted even after adjusting for confounding factors like age, education, and comorbidity burden.

Conclusions:

• Prescription of evidence-based HF medications is not associated with lower global cognitive function scores in rural HF patients.
• These findings suggest that guideline-directed medical therapy for HF can be safely prescribed without exacerbating cognitive deficits.
• Encourages adherence to evidence-based treatment protocols for heart failure management, irrespective of cognitive status.